




The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 365%, being 111% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	26,386
Cost of Goods Sold	17,689
Intangible Assets	12,685
Liabilities, Current	5,948
Liabilities, Non-Current	0
Other Assets	96
Other Compr. Net Income	-1,433
Other Expenses	2,317
Other Liabilities	4,842
Other Net Income	184
Other Revenues	32,464
Property and Equipment	13,041
Research and Development	663
Selling, General and Administrative Expense	8,589

Output Variable	Value in 1000 USD
Assets	52,208
Liabilities	10,790
Expenses	29,258
Revenues	32,464
Stockholders Equity	41,418
Net Income	3,390
Comprehensive Net Income	2,674
BaseVar	63,168
ECR before LimitedLiability	295%
Economic Capital Ratio	365%